• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

甲状腺素与高密度脂蛋白及载脂蛋白A-I结合的特性研究

Characterization of the binding of thyroxine to high density lipoproteins and apolipoproteins A-I.

作者信息

Benvenga S, Cahnmann H J, Gregg R E, Robbins J

机构信息

Clinical Endocrinology Branch, National Institute of Diabetes, Digestive and Kidney Diseases, Bethesda, Maryland 20892.

出版信息

J Clin Endocrinol Metab. 1989 Jun;68(6):1067-72. doi: 10.1210/jcem-68-6-1067.

DOI:10.1210/jcem-68-6-1067
PMID:2498379
Abstract

We studied binding of T4 to the lipid-complexed apolipoproteins (apo) of high density lipoproteins (HDL), the major lipoprotein carrier of thyroid hormones in human plasma, and to lipid-free apoA-I. HDL isolated from fresh normal plasma by ultracentrifugation (density, 1.063-1.210 g/mL) was photoaffinity labeled with [3,5-(125)I]T4 and analyzed by sodium dodecyl sulfate-polyacrylamide gel electrophoresis. Two bands corresponding to apoA-I (28.3K) and apoC-II or apoC-III (8.6-9.2K) were seen, and their radioactivity decreased by 50-60% when labeled in the presence of 1 mumol/L T4. Photoaffinity labeling of isolated apoA-I also was demonstrated and was decreased 74% by 1 mumol/L T4, suggesting a higher affinity of the lipid-free protein for T4. T4 binding of isolated apoA-I was optimal at pH 7-8, reached a maximum after 1 h at 23 C, and decreased after incubation at 37 C. Scatchard analysis revealed a single T4-binding site with a Ka of 7.5 x 10(7) L/mol at 23 C, pH 8.2. The potency of T4 analogs as inhibitors of T4 binding to isolated apoA-I was L-T4 = D-T4 = triiodothyroacetic acid = L-rT3 much greater than L-T3 much greater than L-thyronine. The binding of T4 to apoA-I was reduced by known inhibitors of T4 binding to serum proteins (diclofenac = mefenamic acid = furosemide = 8-anilinonaphthalene sulfonic acid much greater than dilantin greater than heparin greater than barbital) and by lipids (unsaturated fatty acids greater than cholesterol = cholesterol esters = phospholipids greater than saturated fatty acids = diglycerides = triglycerides). We conclude that the binding of T4 to HDL is mediated by a specific interaction of the hormone with apoA-I and with apoC-II and/or apoC-III. Since the lipid constituents of HDL inhibit T4 binding to apoA-I, the HDL subfraction in plasma that carries most of the HDL-bound T4 should be one with a low lipid content.

摘要

我们研究了甲状腺素(T4)与高密度脂蛋白(HDL)的脂质复合载脂蛋白(apo)以及与无脂质载脂蛋白A-I的结合情况。HDL是人类血浆中甲状腺激素的主要脂蛋白载体。通过超速离心法(密度为1.063 - 1.210 g/mL)从新鲜正常血浆中分离出HDL,用[3,5-(125)I]T4进行光亲和标记,然后通过十二烷基硫酸钠 - 聚丙烯酰胺凝胶电泳进行分析。观察到两条分别对应于载脂蛋白A-I(28.3K)和载脂蛋白C-II或载脂蛋白C-III(8.6 - 9.2K)的条带,当在1 μmol/L T4存在下进行标记时,它们的放射性降低了50 - 60%。还证实了对分离出的载脂蛋白A-I进行光亲和标记,并且1 μmol/L T4使其放射性降低了74%,这表明无脂质蛋白对T4具有更高的亲和力。分离出的载脂蛋白A-I与T4的结合在pH 7 - 8时最佳,在23℃下1小时后达到最大值,在37℃孵育后降低。Scatchard分析显示在23℃、pH 8.2条件下有一个单一的T4结合位点,其解离常数(Ka)为7.5×10(7) L/mol。T4类似物作为T4与分离出的载脂蛋白A-I结合的抑制剂的效力为:L-T4 = D-T4 = 三碘甲状腺乙酸 = L-rT3远大于L-T3远大于L-甲状腺素。已知的T4与血清蛋白结合的抑制剂(双氯芬酸 = 甲芬那酸 = 呋塞米 = 8 - 苯胺基萘磺酸远大于苯妥英大于肝素大于巴比妥)以及脂质(不饱和脂肪酸大于胆固醇 = 胆固醇酯 = 磷脂大于饱和脂肪酸 = 甘油二酯 = 甘油三酯)会降低T4与载脂蛋白A-I的结合。我们得出结论,T4与HDL的结合是由该激素与载脂蛋白A-I以及载脂蛋白C-II和/或载脂蛋白C-III的特异性相互作用介导的。由于HDL的脂质成分会抑制T4与载脂蛋白A-I的结合,血浆中携带大部分与HDL结合的T4的HDL亚组分应该是脂质含量低的那种。

相似文献

1
Characterization of the binding of thyroxine to high density lipoproteins and apolipoproteins A-I.甲状腺素与高密度脂蛋白及载脂蛋白A-I结合的特性研究
J Clin Endocrinol Metab. 1989 Jun;68(6):1067-72. doi: 10.1210/jcem-68-6-1067.
2
Thyroxine binding to the apolipoproteins of high density lipoproteins HDL2 and HDL3.甲状腺素与高密度脂蛋白HDL2和HDL3的载脂蛋白结合。
Endocrinology. 1992 Dec;131(6):2805-11. doi: 10.1210/endo.131.6.1446618.
3
The thyroxine-binding site of human apolipoprotein-A-I: location in the N-terminal domain.人载脂蛋白A-I的甲状腺素结合位点:位于N端结构域
Endocrinology. 1991 Jan;128(1):547-52. doi: 10.1210/endo-128-1-547.
4
Thyroid hormone binding to isolated human apolipoproteins A-II, C-I, C-II, and C-III: homology in thyroxine binding sites.甲状腺激素与分离出的人载脂蛋白A-II、C-I、C-II和C-III的结合:甲状腺素结合位点的同源性
Thyroid. 1994 Fall;4(3):261-7. doi: 10.1089/thy.1994.4.261.
5
Characterization of thyroid hormone binding to apolipoprotein-E: localization of the binding site in the exon 3-coded domain.甲状腺激素与载脂蛋白E结合的特性:结合位点在第3外显子编码结构域中的定位。
Endocrinology. 1993 Sep;133(3):1300-5. doi: 10.1210/endo.133.3.8365370.
6
The 27-kilodalton thyroxine (T4)-binding protein is human apolipoprotein A-I: identification of a 68-kilodalton high density lipoprotein that binds T4.
Endocrinology. 1989 Mar;124(3):1265-9. doi: 10.1210/endo-124-3-1265.
7
[Specific binding of iodothyronines with apolipoprotein A-1 in high density lipoprotein particle isolated from human serum by affinity chromatography on thyroxine-sepharose].[通过甲状腺素-琼脂糖亲和层析从人血清中分离的高密度脂蛋白颗粒中碘甲状腺原氨酸与载脂蛋白A-1的特异性结合]
Biokhimiia. 1990 Nov;55(11):2002-10.
8
Human intestinal lipoproteins. Studies in chyluric subjects.人肠道脂蛋白。乳糜尿患者的研究。
J Clin Invest. 1979 Jul;64(1):233-42. doi: 10.1172/JCI109444.
9
[A new property of known proteins: specific binding of thyroid hormones by human plasma apolipoproteins].[已知蛋白质的一种新特性:人血浆载脂蛋白与甲状腺激素的特异性结合]
Biokhimiia. 1994 May;59(5):625-38.
10
Formation of apolipoprotein-specific high-density lipoprotein particles from lipid-free apolipoproteins A-I and A-II.由无脂载脂蛋白A-I和A-II形成载脂蛋白特异性高密度脂蛋白颗粒。
Biochem J. 1999 Feb 1;337 ( Pt 3)(Pt 3):445-51.

引用本文的文献

1
Non-Exosomal and Exosomal Circulatory MicroRNAs: Which Are More Valid as Biomarkers?非外泌体和外泌体循环微小RNA:哪种作为生物标志物更有效?
Front Pharmacol. 2020 Jan 20;10:1500. doi: 10.3389/fphar.2019.01500. eCollection 2019.
2
HDL and cholesterol: life after the divorce?高密度脂蛋白(HDL)和胆固醇:离婚后的生活?
J Lipid Res. 2014 Jan;55(1):4-12. doi: 10.1194/jlr.R035964. Epub 2013 Mar 19.
3
Thyroxine binding to members and non-members of the serine protease inhibitor family.甲状腺素与丝氨酸蛋白酶抑制剂家族成员及非成员的结合。
J Endocrinol Invest. 2002 Jan;25(1):32-8. doi: 10.1007/BF03343958.